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The pathogenetic roles of 8q24 amplified segments in leukemic cells with double minute chromosomes remain to
be verified. Through comprehensive molecular analyses of 8q24 amplicons in leukemic cells from an acute
myelogenous leukemia (AML) patient and AML-derived cell line HL60 cells, we identified two novel fusion genes
between NSMCE2 and long noncoding RNAs (lncRNAs), namely, PVT1-NSMCE2 and BF104016-NSMCE2. Our study
suggests that 8q24 amplicons are associated with the emergence of aberrant chimeric genes between NSMCE2 and
oncogenic lncRNAs, and also implicate that the chimeric genes involving lncRNAs potentially possess as-yet-unknown
oncogenic functional roles.
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To gain insight into the role(s) of double minute chromo-
somes (dmins) in leukemia, we cytogenetically/molecularly
analyzed 8q24 amplicons in patient-derived leukemic cells
and AML-derived cell line (HL60) (See Additional file 1 for
supplementary materials and methods). The patient was a
71-year-old female with AML (M2). The G-banding karyo-
type of leukemic cells was 47, XX, +mar [2]/48, XX, idem,
+mar [6]/46, XX [7], containing two marker chromosomes
(mars) from chromosome 8 (Figure 1a and b). DNA copy
number analysis (CNA) revealed 13 high-level amplicons on
8q22.1-q24.2 (98.43 Mb-134.16 Mb) (Additional file 2:
Table S1). SKY analysis of HL60 cells containing the 8q24
amplicons revealed that the representative karyotype was 44,
X, der(5)t(5;17)(q11.2;q11.2), t(7;16;9)(q34;q24;p21), t(9;14)
(q22;q22), +13, -15, -17, der(21)t(15;21)(q22;q21) [1]. CNA
revealed several amplicons on 8q24.13-q24.12 (126.25 Mb-
130.75 Mb) in the HL60 cells (Figure 2a and b).* Correspondence: junkuro@koto.kpu-m.ac.jp
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unless otherwise stated.Consequently, three common amplicons were identified be-
tween 8q24.13-21 in the patient and the HL60 cells; i.e., the
regions covering NSMCE2 (8q24.13), PVT1 (8q24.21) and
CCDC26 (8q24.21) (Figures 1c and 2b). Further investiga-
tion revealed three fusion transcripts between PVT1 exon
1a and NSMCE2 exon 3 in the patient (Figure 1d and e),
and a fusion gene between exon 6 of NSMCE2 and exon 1
of BF104016, a noncoding RNA sharing the sequence of
CCDC26 exon 4 (Additional file 3: Figure S1) (Additional
file 4: Table S2), in the HL60 cells (Figure 2c-e). Both the
NSMCE2 and PVT1 genes were amplified and located in a
micronucleus in the patient (Figure 1f-i), and the genomic
junction of 5’-PVT1-NSMCE2-3’ was located within intron
1 of PVT1 and at 5’ upstream of exon 1 of NSMCE2
(Figure 1j and k) (Additional file 5: Figure S3). In the HL60
cells, amplification of 3’NSMCE2 and 5’CCDC26 was co-
localized on der(13)hsr(8), ins(2;8) and dmins (Figure 2e-h)
(Additional file 5: Figure S3). Aberrant NSMCE2 transcripts
were higher than normal NSMCE2 transcripts in the patient
and the HL60 cells, while NSMCE2 protein expression did
not correlate with normal or abnormal NSMCE2 transcripts
among the leukemic patient cells or the HL60 cells, suggest-
ing the presence of regulatory mechanisms other than tran-
scription (Additional file 6: Figure S2).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Identification of PVT1-NSMCE2 in the leukemic patient cells. (a) G-banding analysis. Arrow indicates two marker chromosomes
(mars). (b) SKY analysis for the patient identified two mars derived from chromosome 8 (arrows). (c) Copy number changes at 8q24 detected by
high-resolution oligonucleotide array. NSMCE2, TRIB1, MYC, PVT1, CCDC26, GSDMC, and FAM49B are amplified. The direction of the arrows reflects the
direction of gene transcription. NG: no gene. (d) Detection of three PVT1-NSMCE2 fusion transcripts by RT-PCR. Primers were P1S and NSMCE2-Ex4AS
for 5'-PVT1-NSMCE2-3'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. (e) Sequence analysis of NSMCE2 fusion transcript
in the patient. (f) FISH finding of the patient using PVT1 probe. Multiple red signals indicate extrachromosomal amplification of 5’PVT1 on dmins.
Co-localized red and green signals indicate normal PVT1. Inset shows 5’PVT1 amplification in a micronucleus equivalent of mar (arrow). (Additional file
5: Figure S3) (g) FISH finding from the patient using an NSMCE2 probe. Intense yellow signals indicate amplification of NSMCE2 on mars and
co-localized red and green signals signify normal NSMCE2 on chromosome 8. Inset shows NSMCE2 amplification in a micronucleus equivalent of mar
(arrow). (h and i) DAPI pictures of metaphase cells corresponding to (f) and (g). Arrows indicate mars. In metaphase, NSMCE2 amplification was
detectable on mars. 5’PVT1 amplification were observed on dmins, however, PVT1 FISH probe sets could not identify mars because of the background
dmins (f and h). (j) Results of LDI-PCR. Primers were NSM38374 and NSM38666 for 5'-PVT1-NSMCE2-3'. Lane Pt.1: leukemic cells from the patient; lane
N: water; lane M: size marker. (Additional file 4: Table S2) (k) Genomic mapping of PVT1 and NSMCE2 exons and breakpoint. White vertical boxes
represent exons; dotted line represents breakpoint of PVT1 and NSMCE2 in the patient detected by LDI-PCR. Horizontal line indicates the location
of miRNAs.
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Figure 2 Identification of BF104016-NSMCE2 in HL60. (a) Representative SKY karyotype of HL60 cells. Arrowheads indicate material inserted
from chromosome 8 on ins(2;8) and der(13)hsr(8). Inset shows pseudocolor image of ins(2;8). (b) Copy number changes at 8q24 detected by
high-resolution oligonucleotide array. NSMCE2, TRIB1, MYC, PVT1 and CCDC26 are amplified in HL60. The direction of the arrows reflects the
direction of the gene transcription. NG: no gene. (c) Bubble PCR products detected by nested PCR using NVAMP1 and NSMCE2-Ex7AS for the first
PCR, and NVAMP2 and NSM695 for the second. M: size marker. (d) Sequence analysis of NSMCE2 fusion transcript of HL60. (e) Detection of
BF104016-NSMCE2 fusion transcripts by RT-PCR. Primers were BF104-1S and NSMCE2-Ex7AS for 5'-BF104016-NSMCE2-3'. Lanes N: water. (Additional
file 4: Table S2) (f) FISH finding of HL60 using CCDC26 probe. Intense co-localized red and green signal indicates amplification of the CCDC26
gene on der(13)hsr(8) (arrowhead). A co-localized red and green signal is seen on ins(2;8) (arrow). Multiple green signals indicate amplification of
the 5’CCDC26 gene on dmins. Co-localized red and green signals show normal CCDC26. (g) FISH finding of HL60 using NSMCE2 probe. Intense
green signals indicate amplification of 3’NSMCE2 on der(13)hsr(8) (arrowhead) and ins(2;8) (arrow). Multiple red and green signals indicate amplification
of the NSMCE2 gene on dmins. Co-localized red and green signals indicate normal chromosomal NSMCE2. (Additional file 5: Figure S3) (h and i) DAPI
pictures of metaphase cells corresponding to (f) and (g). Arrow and arrowhead indicate ins(2;8) and der(13)hsr(8), respectively.
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ies demonstrating that segmental genome amplification of
8q24 contains recurrent PVT1 fusion genes, which might
be generated by chromothripsis [2,3]. Both lncRNAs,
PVT1 and CCDC26, harbor retroviral integration sites
and are transcribed into multiple splice forms [4-6]. PVT1
overexpression is induced by MYC or p53, contributing to
suppression of apoptosis [7-9], whereas PVT1 produces
six annotated microRNAs that have been implicated in
oncogenesis [3,10,11]. The chimeric transcripts involving
PVT1 may also regulate the expression of as-yet unspeci-
fied target genes through “enhancer-like functions” [12].
CCDC26 amplification has been also identified as a recur-
rent abnormality that is associated with the response to
retinoic acid-induced differentiation in AML [1,11,13-16].
This study is the first to identify NSMCE2-associated
fusion genes in AML [17-19]. Knockdown of NSMCE2
induces chromosomal instability and increases the
frequency of chromosomal breakage and loss [20]. We
speculate that NSMCE2 gene rearrangement may poten-
tially influence its function. Collectively, our study identi-
fied novel PVT1-NSMCE2 and CCDC26-NSMCE2 fusion
genes that may play functional roles in leukemia.Additional files
Additional file 1: Supplementary material information.
Additional file 2: Table S1. CNAG analysis of the region between the
MTDH and LRRC6 genes on 8q24 in patient 1 with marker chromosomes.
Results show the genomic size of the eight amplified segments that
were selected based on the existence of known genes within them and
their approximate positions.
Additional file 3: Figure S1. Association between CCDC26 and
BF104016 at 8q24.21. The scale indicates the region 8q24.21. White boxes
and grey boxes indicate exons of CCDC26 and BF104016 on the genetic
locus at 8q24.21, respecitively. Vertical black lines indicate exons on the
CCDC26 isoform. According to the NCBI database, isoform 1 (BC070152.1)
consists of four (1-2-3-4) exons, and isoform 2 (BC026098.1) consists of
three (1a-3-4) exons. BF104016 consists of 2 exons. The sequence of
BF104016 exon 2 is partly consistent with that of CCDC26 exon 4. ORF:
hypothetical open reading frame.
Additional file 4: Table S2. Sequences of the primers used in this
study.
Additional file 5: Figure S3. Identification of breakpoints region at
8q24 by FISH. Upper panel: location of FISH probes shown as color bars
and position of NSMCE2, TRIB1, MYC, and PVT1 genes at 8q24. Vertical
black lines indicate exons of NSMCE2, PVT1, and BF104016. Lower panel:
mapping of breakpoint in leukemic cells of patient 1 and HL60. Gray
boxes indicate amplified regions detected.
Additional file 6: Figure S2. Expression of NSMCE2 in patient 1 and
AML-derived cell lines. (a) NSMCE2 mRNA levels measured by RQ-PCR
(n=3, mean ± SD). Theoretically, the NSMCE2 7-8 primer/probe can
amplify both normal and aberrant NSMCE2 transcripts, while the NSMCE2
2-3 primer/probe set which can amplify only normal NSMCE2 transcript.
NSMCE2 mRNA levels were normalized to β-actin and are relative to the
control mRNA extracted from normal BM cells. NSMCE2 mRNA levels
amplified by the NSMCE2 7-8 primer/probe set are higher than those
amplified by the NSMCE2 2-3 primer/probe set in patient 1, HL60 and
KG1 cells. (b) Protein analysis using the anti-NSMCE2 antibody in cells.
Blot for β-actin was used as loading control. Lane 1: normal BM; lane 2:KG1; lane 3: HL60. (c and d) IHC analysis of NSMCE2 expression in BM of
patient 1 (c) and normal BM (d). NSMCE2 expression of leukemic cells was
not higher than that of normal BM cells. Monocytes and megakaryocytes
showed strong positive signals in their cytoplasm.
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